Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21


This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce TH2 immune responses associated with fibrosis in animal models.

The causes of chronic tissue fibrosis are diverse and the market for a therapeutic that targets fibrosis is large. Fibrosis is associated with diverse causes which include: genetic diseases (such as cystic fibrosis); autoimmune diseases (such as scleroderma); chronic viral infections (such as hepatitis), parasitic infections (such as schistosomiasis); and occupational exposures to causative agents (such as asbestosis). Additionally, many cases of tissue fibrosis are idiopathic.

Potential Commercial Applications: Competitive Advantages:
  • The treatment or amelioration of tissue fibrosis.
 


Inventors:

Thomas Wynn (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,910,105 issued 2011-03-22
US Application No. 11/402,885
PCT Application No. PCT/US2006/013829
US Application No. 13/030,840
International rights available.

Publications:
Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. PMID 16778988

Licensing Contact:
James Robinson,
Email: james.robinson4@nih.gov
Phone: 301-761-7542

OTT Reference No: E-250-2005-0
Updated: May 16, 2018